Extremely high-risk patients with acute coronary syndrome: How "extreme" should lipid-lowering therapy be if the LDL-C target <40 mg/dl is considered?

被引：5

作者：

Rallidis, Loukianos S. ^{[1
]}

Tsamoulis, Donatos ^{[2
]}

Leventis, Ioannis ^{[3
]}

Kalogeras, Petros ^{[4
]}

Delakis, Iosif ^{[5
]}

Samiotis, Elefterios ^{[1
]}

Kalantzis, Charalampos ^{[6
]}

Malkots, Belkis ^{[7
]}

Tasoulas, Dimitrios ^{[8
]}

Bouratzis, Vasileios ^{[4
]}

Eleutheriou, Dimitris ^{[9
]}

Dalos, Styliano ^{[10
]}

Potoupni, Victoria ^{[11
]}

Zervakis, Stelio ^{[12
]}

Xygka, Georgia ^{[13
]}

Miliotou, Argyro ^{[14
]}

Papathanasiou, Konstantinos A. ^{[1
,15
]}

Vlachopoulos, Charalambos ^{[6
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Univ Gen Hosp ATTIKON, Med Sch, Dept Cardiol 2, Athens, Greece

[2] Thriasio Gen Hosp, Dept Cardiol, Elefsina, Greece

[3] Univ Gen Hosp Larissa, Dept Cardiol, Larisa, Greece

[4] Univ Hosp Ioannina, Dept Cardiol 2, Ioannina, Greece

[5] Gen Hosp Nikea, Dept Cardiol 1, Piraeus, Greece

[6] Natl & Kapodistrian Univ Athens, Hippokrat Hosp, Med Sch, Dept Cardiol 1, Athens, Greece

[7] Democritus Univ Thrace, Med Sch, Dept Cardiol, Dragana, Alexandroupolis, Greece

[8] Gen Hosp Nikea, Dept Cardiol 2, Piraeus, Greece

[9] Gen Hosp Athens Evangelismos, Dept Cardiol 2, Athens, Greece

[10] Univ Gen Hosp Thessaloniki, Dept Cardiol 1, AHEPA, Thessaloniki, Greece

[11] Aristotle Univ Thessaloniki, Hippokrat Univ Hosp, Dept Cardiol 3, Thessaloniki, Greece

[12] Heraklion Univ Hosp, Dept Cardiol, Iraklion, Greece

[13] Patras Univ Hosp, Dept Cardiol, Patras, Greece

[14] Univ Athens, Alexandra Hosp, Dept Clin Therapeut, Athens, Greece

[15] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Med Sch, Dept Cardiol 2, Athens 12462, Greece

来源：

KARDIOLOGIA POLSKA | 2023年 / 81卷 / 10期

关键词：

D O I：

10.33963/KP.a2023.0147

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1012 / 1014

页数：3

共 48 条

[31] Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C
Katzmann, Julius L.
Sorio-Vilela, Francesc
Dornstauder, Eugen
Fraas, Uwe
Smieszek, Timo
Zappacosta, Sofia
Laufs, Ulrich
CLINICAL RESEARCH IN CARDIOLOGY, 2022, 111 (03) : 243 - 252
[32] Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C
Julius L. Katzmann
Francesc Sorio-Vilela
Eugen Dornstauder
Uwe Fraas
Timo Smieszek
Sofia Zappacosta
Ulrich Laufs
Clinical Research in Cardiology, 2022, 111 : 243 - 252
[33] Echolucency of carotid plaque is useful for selecting high-risk patients with chronic coronary artery disease who benefit from intensive lipid-lowering therapy
Uematsu, Manabu
Nakamura, Takamitsu
Horikoshi, Takeo
Yoshizaki, Toru
Watanabe, Yosuke
Kobayashi, Tsuyoshi
Saito, Yukio
Nakamura, Kazuto
Obata, Jun-Ei
Kugiyama, Kiyotaka
JOURNAL OF CARDIOLOGY, 2021, 77 (06) : 590 - 598
[34] Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States
Baum, Seth J.
Rane, Pallavi B.
Nunna, Sasikiran
Habib, Mohdhar
Philip, Kiran
Sun, Kainan
Wang, Xin
Wade, Rolin L.
AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 6
[35] The current LDL-C target <1.4mmol/l of the ESC is achieved in less than 16% of patients with Coronary Heart Disease despite effective lipid-lowering therapy: data from the LLT-R registry
Noack, F.
Schwaab, B.
Voeller, H.
Eckrich, K.
Guha, M.
Bongarth, C.
Heine, V
Schlitt, A.
EUROPEAN HEART JOURNAL, 2020, 41 : 2998 - 2998
[36] Prevalence of reaching target low-density lipoprotein cholesterol (LDL-C) in very high -risk patients using high intensity lipid-modifying therapy
Khader, A. Omar
Van der Brug, S.
Liem, A.
Hamer, B.
Groenemeijer, B.
Martens, F.
Alings, M.
EUROPEAN HEART JOURNAL, 2022, 43 : 1412 - 1412
[37] Low-density lipoprotein cholesterol target value attainment based on 2019 ESC/EAS guidelines and lipid-lowering therapy titration for patients with acute coronary syndrome
Farmakis, Ioannis
Zafeiropoulos, Stefanos
Pagiantza, Areti
Boulmpou, Aristi
Arvanitaki, Alexandra
Tampaki, Athina
Kosmidis, Diamantis
Nevras, Vassileios
Markidis, Eleftherios
Papadimitriou, Ioannis
Karvounis, Haralambos
Giannakoulas, George
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (19) : 2314 - 2317
[38] The new LDL-C target <55 mg/dL is achieved by less than 40% of very high risk patients with familial hypercholesterolaemia despite receiving PCSK9 inhibitors: real world data
Rallidis, L.
Vlachopoulos, C.
Liberopoulos, E.
Skoumas, I
Kiouri, E.
Koutagiar, I
Anastasiou, G.
Kosmas, N.
Tousoulis, D.
Iliodromitis, E.
EUROPEAN HEART JOURNAL, 2020, 41 : 2999 - 2999
[39] Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome receiving contemporary lipid-lowering therapy
Nakazawa, M.
Arashi, H.
Inagaki, Y.
Otsuki, H.
Yamaguchi, J.
Ogawa, H.
Hagiwara, N.
EUROPEAN HEART JOURNAL, 2020, 41 : 1639 - 1639
[40] Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥50% reduction in high-risk patients: Results from VOYAGER
Karlson, Bjorn W.
Nicholls, Stephen J.
Lundman, Pia
Palmer, Mike K.
Barter, Philip J.
ATHEROSCLEROSIS, 2013, 228 (01) : 265 - 269

← 1 2 3 4 5 →